Regeneron Pharmaceuticals experienced a steep pre-market decline after announcing that its Phase 3 study assessing fianlimab, a LAG-3 inhibitor, in combination with cemiplimab as first-line treatment for unresectable or metastatic melanoma did not achieve statistical significance for the trial's primary endpoint. The endpoint measured improvement in progression-free survival compared with pembrolizumab monotherapy.
While the high-dose combination arm produced a median progression-free survival of 11.5 months versus 6.4 months for the pembrolizumab comparator - a numeric improvement of 5.1 months that could be described as biologically encouraging - the outcome fell short of statistical significance. That statistical shortfall effectively removes a clear near-term regulatory pathway for fianlimab in this melanoma indication.
Investor reaction was immediate and pronounced. Shares fell 10.5% in pre-open trading to trade at $625, below the prior close of $698.25. The price move positioned the stock nearer to the lower bound of its 52-week trading range, which spans $476.49 to $821.11.
Analyst responses added to selling pressure. Citi downgraded the stock from Buy to Neutral and cut its price target from $900 to $700. Citi's adjustment reflected removing fianlimab's melanoma opportunity from its valuation models, a move that narrows the company's near-term upside expectations tied to that program.
The trial miss comes amid other development setbacks for fianlimab. The program had previously failed to advance to Phase 3 in non-small cell lung cancer after Phase 2 data did not support continued development in that indication, further constraining the drug's addressable opportunity.
Market conditions provided little cushion. Major U.S. indices were trading lower as the company reported the result, with the S&P 500 down 1.24%, the Dow Jones Industrial Average off 1.07%, and the NASDAQ declining 1.54%. That risk-off environment amplified the company-specific impact of the negative clinical news.
From a commercial and portfolio standpoint, Regeneron still retains key franchises. The company continues to run its Opdualag head-to-head study and maintains its core products including Dupixent and Eylea HD. However, today's Phase 3 result removes a prominent near-term catalyst that some investors had been anticipating and reduces the potential contribution from a melanoma indication estimated at a $2 to $3 billion addressable market.
In aggregate, the combination of a high-profile Phase 3 miss in a multi-billion dollar opportunity, a material analyst downgrade, and a weak macro market led to the pre-market share price of $625. The result narrows near-term regulatory and commercial pathways for fianlimab in melanoma and leaves investors to reassess the program's role within Regeneron's broader pipeline and valuation.